Tag Archive for: fordadistrogene movaparvovec

Sarepta wins full approval and label expansion for DMD gene therapy

, ,

Sarepta Therapeutics’ gene therapy Elevidys will be available to Duchenne muscular dystrophy (DMD) patients who are at least 4 years old, regardless of whether they can walk, the FDA said Thursday.

Read more
/by

Pfizer halts dosing in late-stage DMD study following death of young patient

Pfizer’s investigational Duchenne muscular dystrophy gene therapy fordadistrogene movaparvovec has been hit with another patient death, forcing the pharma to pause dosing in its Phase III study.

Read more
/by